SX-1
SX-2-1
SX-3

product

Let's take our development to a higher level

more>>

about us

Quality First, Safety Guaranteed

what we do

Shanghai Dumi Biotechnology Co., LTD is committed to R&D and production of chemical products. We strive to provide the best products and service to customers all over the world. We have our own factory, our own team, and a complete service system.
For us, quality assurance is our commitment to our customers.

more>>
learn more

We guarantee that your package will pass 100% through the US, UK, Australia, Netherlands, Canada, France, Germany, Spain, Belgium, Sweden, Poland, Russian, Ukraine, Kazakhstan, Czech Republic, Slovakia, Portugal. We have freight forwarders in these countries / regions, and our customs clearance company will clear your parcels without any customs issues, sometimes even 1000 kg. Door to door service. Make sure you receive 100% of the goods. Let you have a good experience of our strong freight capacity.

Click for manual

Product style

  • Address

    Room J, Area E, 1 / F, Building 4, No. 358_368, Kefu Road, Jiading District, Shanghai

  • Phone

    +8617172178855

  • Email

    victoria@chinadumi.com

news

We will increase and strengthen the partnerships we have.

Synthetic Death By Parp Inhibitors Can Put Cancer Cells

Although Iniparib has a poor track record of failure, PARP inhibitors have returned to the breast cancer arena after breaking through the ovarian cancer barrier

Biosynthesis Pathway Of N-Methylpyrrolidine And...

Toluidine alkaloids such as anisodamine and cyperine have important biological activities and clinical medicinal value.These alkaloids are mainly obtained by traditional extraction methods of the o...
more>>

A New Biocatalysis Method For The Synthesis Of ...

As the skeleton structure of many bioactive natural products and drugs (such as the cough suppressant dexamethadine), moralane can be obtained from the key intermediate 1-benzyl octahydroisoquinoli...
more>>

Synthetic Death By Parp Inhibitors Can Put Canc...

Although Iniparib has a poor track record of failure, PARP inhibitors have returned to the breast cancer arena after breaking through the ovarian cancer barrier, with Olaparib and Talazoparib succe...
more>>